This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.—
Since the publication of my article, "Standardization of Drug Names" (229:541, 1974), stimulated the production of two editorials and a commentary, it appears clear that, in spite of minor criticisms, there is deep interest in the problem. It can also be maintained that my conclusions are not invalidated. There is indeed "a growing opinion that practicing physicians and medical teachers should strongly promote the abolition of multiple proprietary names." Furthermore, the American Pharmaceutical Association, at its August meeting, adopted a resolution to this effect.One editorial (229:559, 1974) recalled that an earlier editorial published a decade ago asserted that "physicians should be encouraged regularly to use nonproprietary names," followed by a qualification almost identical in intent with my conclusion, which reads in part: "At the same time, the prescribing physician must be free to designate the manufacturer or brand when, in his judgment, it is advantageous to
Allan FN. Standardization of Drug Names. JAMA. 1974;230(4):540. doi:10.1001/jama.1974.03240040018019
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: